RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

WHY IT MATTERS WHY IT MATTERS "Current early-warning scores that rely on threshold-based methods often suffer from low precision, leading to a high number of alarms and notifications. Advanced AI-driven machine learning models have the potential to deliver significantly greater precision, reducing unnecessary alerts/notifications, thus enabling healthcare professionals to better focus their time on delivering quality patient care," said Dr.Gurpreet Singh, CEO and Founder of Respiree...

WHY IT MATTERS

"Current early-warning scores that rely on threshold-based methods often suffer from low precision, leading to a high number of alarms and notifications. Advanced AI-driven machine learning models have the potential to deliver significantly greater precision, reducing unnecessary alerts/notifications, thus enabling healthcare professionals to better focus their time on delivering quality patient care," said Dr. Gurpreet Singh, CEO and Founder of Respiree.

The 1Bio™AI-Acute is readily available to healthcare professionals through Respiree's 1Bio™ platform, which recently received regulatory clearance together with the RS001 wearable device. With this milestone, the 1Bio™AI-Acute toolbox, the 1Bio™platform, and the RS001 wearable are all now approved by HSA.

With the HSA approval for the 1Bio™AI-Acute toolbox, Respiree is now setting its sights on expanding the 1Bio™AI-Acute regulatory approvals across other APAC and ANZ regions, as well as in the United States, in the coming months.

HSA's approval of the 1Bio™AI-Acute toolbox follows the validation study that was recently peer-reviewed and published in the Mayo Clinic Proceedings.

About Respiree

Respiree™ is an AI/ML health tech company building clinically-validated AI for managing disease progression. Respiree™ products are CE marked and has received regulatory clearances from the Therapeutic Goods Administration and the United States Food and Drug Administration (FDA).

Logo - https://mma.prnewswire.com/media/2839265/1Bio_AI.jpg

View original content:https://www.prnewswire.co.uk/news-releases/respiree-secures-singapore-hsa-approval-for-its-ai-enabled-1bioai-software-to-support-acute-deterioration-detection-302634208.html